Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
Investor Relations
Latest Financial Results
Q3 2020
Quarterly Results
Ended Sep 30, 2020
Stock Information
Symbol
NYSE American: OGEN
Price
Change
Day Range
52 Wk Range
Company Overview
Oragenics is focused on the creation of the TerraCoV2 immunization product candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. In addition, Oragenics, Inc. has established an exclusive worldwide channel collaboration with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.
Contact Information
Investor Relations
CORE IR
John Marco
Managing Director
T: 310-819-2948
johnm@coreir.com
Transfer Agent
Continental Stock Transfer and Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000